The classic BCR-ABL-negative myeloproliferative disorders (MPDs) include polycythemia vera (PV), essential thrombocythemia (ET), and agnogenic myeloid metaplasia. Included in this latter group are also postthrombocythemic and postpolycythemic myeloid metaplasia (1). This last group has been the subject of focus and nomenclature changes by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF) is designated for de novo presentations, and the myelofibrosis (MF) that develops in the setting of either ET or PV is referred to as post-ET MF or post-PV MF, respectively.
|Original language||English (US)|
|Title of host publication||Myeloproliferative Disorders|
|Subtitle of host publication||Biology and Management|
|Number of pages||18|
|State||Published - Jan 1 2007|
ASJC Scopus subject areas